Paper86634
Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity.
Vánky FT and 3 others. J Natl Cancer Inst, 1979. Cited by 43 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity. Papers, record 86634. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/86634
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytotoxicity, Immunologic | Major topic |
| Neoplasms | Major topic |
| T-Lymphocytes | Major topic |
| Antigens, Neoplasm | |
| Epitopes | |
| Humans | |
| In Vitro Techniques |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 9,617,349 | Enhancement of anti-tumor activity of natural killer cells by BALL-1, a B cell lymphoma line. | Jpn J Cancer Res | 1998 | https://conductscience.org/library/papers/9617349 | PubMed |
| 6,977,725 | Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cells. | Nature | 1982 | https://conductscience.org/library/papers/6977725 | PubMed |
| 6,965,234 | Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes. | Cancer Immunol Immunother | 1982 | https://conductscience.org/library/papers/6965234 | PubMed |
| 6,605,800 | Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. II. Evaluation of 69 patients with lung carcinoma. | Cancer Immunol Immunother | 1983 | https://conductscience.org/library/papers/6605800 | PubMed |
| 6,459,402 | Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor. | J Exp Med | 1982 | https://conductscience.org/library/papers/6459402 | PubMed |
| 6,225,511 | Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture. Clonal analysis of effector cells in cytotoxic and proliferative assays. | Cancer Immunol Immunother | 1983 | https://conductscience.org/library/papers/6225511 | PubMed |
| 6,176,669 | Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. | J Exp Med | 1982 | https://conductscience.org/library/papers/6176669 | PubMed |
| 6,154,767 | Role of alloantigens in natural killing. Allogeneic but not autologous tumor biopsy cells are sensitive for interferon-induced cytotoxicity of human blood lymphcoytes. | J Exp Med | 1980 | https://conductscience.org/library/papers/6154767 | PubMed |
| 3,877,561 | Lysis of fresh human tumour cells by autologous tumour-associated lymphocytes: two distinct types of autologous tumour killer cells induced by co-culture with autologous tumour. | Cancer Immunol Immunother | 1985 | https://conductscience.org/library/papers/3877561 | PubMed |
| 3,552,279 | Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators. | Cancer Metastasis Rev | 1987 | https://conductscience.org/library/papers/3552279 | PubMed |
| 3,499,984 | In vitro generation of tumour-specific lymphocyte reactivity to colonic carcinoma cells. Comparison with normal colonic mucosa cells. | Cancer Immunol Immunother | 1987 | https://conductscience.org/library/papers/3499984 | PubMed |
| 3,455,878 | Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course. | Cancer Immunol Immunother | 1986 | https://conductscience.org/library/papers/3455878 | PubMed |
| 3,262,014 | In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission. | Cancer Immunol Immunother | 1988 | https://conductscience.org/library/papers/3262014 | PubMed |
| 2,950,997 | Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture--no correlation with the postsurgical clinical course. | Cancer Immunol Immunother | 1987 | https://conductscience.org/library/papers/2950997 | PubMed |
| 2,507,488 | Identification of a human T cell clone with the cytotoxic T lymphocyte and natural killer-like cytotoxic function against autologous mammary carcinoma and K562 line. | Jpn J Cancer Res | 1989 | https://conductscience.org/library/papers/2507488 | PubMed |
| 2,470,505 | Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2470505 | PubMed |
| 1,646,074 | Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2. | Cancer Immunol Immunother | 1991 | https://conductscience.org/library/papers/1646074 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/86634
GET https://conductscience.org/api/papers/v1/86634/authors